恆指28,900獲承接收窄逾半跌幅 美團升幅擴至逾9% 藥明生物及石藥升逾4%
港股繼上周累漲665點或2.3%連升兩周後,今早在港交所(00388.HK)、重磅股騰訊(00700.HK)、安踏(02020.HK)、藥明生物(02269.HK)及季度營收倍增美團(03690.HK)支撐高開101點或近0.4%,報29,225欠承接,在金融板塊回吐主導掉頭曾倒跌214點,午後低見28,909喘定,現造29,022,僅倒跌102點或近0.4%,成交額1,118億元。
55隻藍籌普遍下跌,尤其是友邦(01299.HK)重失20天、10天線(100.43元及101.98元)及「紅底股」,最低見98.6元(剛為50天線),現造99.25元,回吐3.8%;匯控(00005.HK)和恆生(00011.HK)分別由逾14個月及16個月高位回吐3%及2.2%,分別低見49.1元(剛為10天線)及161.1元(險守10天線161.05元);中銀(02388.HK)重失10天及20天線(28.25元及28.5元),最低見27.9元,現造28.05元,回吐1.9%。
回購建議獲接納上周五股價創16個月高的長實集團(01113.HK)、九倉置業(01997.HK)、百威亞太(01876.HK)、濠賭股金沙(01928.HK)和銀娛(00027.HK)、電能(00006.HK)及申洲(02313.HK)也跌約2%-3%。
不過,港交所重越百天線(479.45元),最高見487.8元,現造483元,回升1.2%。騰訊扭兩連跌,股價重越20天及10天線(603.5元),最高見612元,現造611.5元,回升1.7%。季度營收倍增獲大行維持正面評級的美團午後升幅擴大,挑戰50天線290.1元,最高見290.8元,現造290元,回升9.4%,結束兩連跌。藥明生物回升4.3%曾高見120.9元;上周獲野村升價至13.7元的石藥(01093.HK)回升4.1%曾高見12.34元創近三年高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.